MedTrace Logo

Fetal Hemoglobin Induction Treatment Metformin

NCT02981329 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2023-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether metformin is effective in the treatment for sickle cell anemia (SCA).

Conditions

Interventions

DRUG

Metformin

Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.

BEHAVIORAL

Questionnaires

Questionnaires will be completed to assess the impact quality of life

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Titilope Fasipe, MD · Baylor College of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-02
Primary Completion
2020-07-20
Completion
2020-07-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02981329 on ClinicalTrials.gov